Related Experiment Video
Updated: Jun 14, 2026
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
Human leucocyte antigen class I and class II antigen expression in malignant fibrous histiocytoma, fibrosarcoma and
M Meissner1, V König, I Hrgovic
1Department of Dermatology, Venerology and Allergology, Johann Wolfgang Goethe-University, Frankfurt, Germany. markus.meissner@kgu.de
Background:
Abnormalities in the expression of human leucocyte antigens (HLA) by tumour cells impair cellular immune responses promoting immune evasion and tumour survival. To date, studies analysing HLA class I and class II expression levels in malignant fibrous histiocytomas, fibrosarcomas and dermatofibrosarcoma protuberans are limited.
Aims:
Therefore, we investigated the in vivo expression profile of HLA class I and class II antigens in 99 malignant fibrous histiocytomas, 20 fibrosarcomas and 34 dermatofibrosarcoma protuberans from different anatomical sites.
Material And Methods:
Immunohistochemistry using monoclonal antibodies to HLA class I and class II antigens was used to define the expression levels of these antigens on respective tumour samples.
Results:
Frequent loss or downregulation of HLA class I and class II expression in malignant fibrous tumours was observed for the different types of tumours examined.
Discussion:
The data presented suggest for the first time a high frequency of HLA class I and class II abnormalities in malignant fibrous histiocytomas, fibrosarcomas and dermatofibrosarcoma protuberans in vivo.
Conclusion:
This information might be useful in the practical and clinical design of tumour vaccination strategies.
